News Headlines
-
Domain Therapeutics And Chime Biologics Announce Manufacturing Agreement To Advance Novel Anti-CCR8 Antibody For Cancer Immunotherapy
3/12/2024
Domain Therapeutics ("Domain"), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), and Chime Biologics, a leading Contract Development and Manufacturing Organization (CDMO) that enables its partners' success in biologics, today announce the signing of a manufacturing service agreement for the production of Domain's best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of manufacturing aims to deliver an effective therapeutic for cancer patients worldwide.
-
Alcami Partners With Tanvex CDMO To Offer A Complete Solution For Biologics Developers
3/12/2024
Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced a new strategic partnership with Tanvex CDMO, a biologics developer offering pre-clinical to commercial biologic CDMO services.
-
Natoli Engineering Welcomes Tablet Tooling Expert Todd Martin
3/11/2024
Natoli Engineering, the world-renowned leader in tablet compression tooling, presses, machine parts, and encapsulation, is excited to announce the hiring of longtime expert in the field, Todd D. Martin, into his new role as Senior Technical Service Engineer. Prior to his role at Natoli, Mr. Martin served as a Senior Tooling Engineer at Wilson Tool International for over five years, and in multiple tooling-related roles for over 22 years at Thomas Engineering.
-
Mikart Announces Validation Of Its New Liquid And Suspension Suite
3/11/2024
Mikart LLC, a leading contract development and manufacturing company, proudly announces the successful validation of its liquid product within its innovative Liquid and Suspension Suite for an Oral Solution Program.
-
Standard Industries Launches A $1 Million AI Challenge To Transform Chemical Innovation
3/7/2024
Standard Industries, a global industrial company, along with its operating business W. R. Grace & Co., a leader in specialty chemicals and materials, launched the Standard Industries Chemical Innovation Challenge: Advancing AI-Assisted Molecular Synthesis.
-
SK bioscience Breaks Ground On Manufacturing Facility Expansion For Extending Product Pipeline
3/7/2024
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that the company broke ground on a major expansion of its vaccine manufacturing plant, L HOUSE, located in Andong, Gyeongsangbuk-do, South Korea.
-
Cellipont Bioservices Announces Grand Opening Of Its Purpose-Built Cell Therapy Manufacturing Facility
3/7/2024
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the grand opening of its purpose-built 76,000 sq. ft. manufacturing facility in The Woodlands, TX.
-
BioCentriq Strengthens Partnership With Pluristyx To Accelerate The Development Of iPSC-Derived NK Cell Therapies
3/7/2024
BioCentriq, Inc., a global cell therapy Contract Development and Manufacturing Organization (CDMO), is proud to announce a significant enhancement to its partnership with Pluristyx Inc., an early stage, privately held biotechnology company specializing in Induced Pluripotent Stem Cell (iPSC) products.
-
Johnson & Johnson Completes Acquisition Of Ambrx
3/7/2024
Johnson & Johnson announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0B, or $1.9B net of estimated cash acquired, as announced on January 8, 2024. The transaction will be accounted for as a business combination.
-
Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line
3/6/2024
Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.